HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA

This article was originally published in The Tan Sheet

Executive Summary

LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations

You may also be interested in...



FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban

FDA Commissioner Mark McClellan, MD/PhD, said the "framework" for the outright ban of ephedra will be based on substantive scientific evidence as the agency prepares to publish the reg

LipoKinetix Cases Prompt Support For Mandatory Supplement AE Reporting

Seven hepatotoxicity adverse event reports linked to Syntrax' LipoKinetix weight-loss supplement further support the need for mandatory AE reporting for supplement manufacturers, University of Pennsylvania researchers say

PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status

An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.

Related Content

Topics

UsernamePublicRestriction

Register

RS131569

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel